- Home
- VRE vs DNTH Comparison
VRE vs DNTH Comparison
Compare VRE & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRE
- DNTH
- Stock Information
- Founded
- VRE 1949
- DNTH 2015
- Country
- VRE United States
- DNTH United States
- Employees
- VRE N/A
- DNTH N/A
- Industry
- VRE Real Estate Investment Trusts
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- VRE Real Estate
- DNTH Health Care
- Exchange
- VRE Nasdaq
- DNTH Nasdaq
- Market Cap
- VRE 1.4B
- DNTH 1.5B
- IPO Year
- VRE 1994
- DNTH N/A
- Fundamental
- Price
- VRE $14.59
- DNTH $35.02
- Analyst Decision
- VRE Buy
- DNTH Strong Buy
- Analyst Count
- VRE 5
- DNTH 10
- Target Price
- VRE $19.20
- DNTH $66.38
- AVG Volume (30 Days)
- VRE 708.8K
- DNTH 699.9K
- Earning Date
- VRE 10-22-2025
- DNTH 11-06-2025
- Dividend Yield
- VRE 2.19%
- DNTH N/A
- EPS Growth
- VRE N/A
- DNTH N/A
- EPS
- VRE N/A
- DNTH N/A
- Revenue
- VRE $285,675,000.00
- DNTH $4,854,000.00
- Revenue This Year
- VRE $6.48
- DNTH N/A
- Revenue Next Year
- VRE $1.33
- DNTH N/A
- P/E Ratio
- VRE N/A
- DNTH N/A
- Revenue Growth
- VRE 5.04
- DNTH 17.87
- 52 Week Low
- VRE $13.69
- DNTH $13.37
- 52 Week High
- VRE $18.85
- DNTH $40.16
- Technical
- Relative Strength Index (RSI)
- VRE 39.00
- DNTH 52.16
- Support Level
- VRE $14.37
- DNTH $33.96
- Resistance Level
- VRE $15.20
- DNTH $40.16
- Average True Range (ATR)
- VRE 0.30
- DNTH 2.10
- MACD
- VRE -0.11
- DNTH -0.95
- Stochastic Oscillator
- VRE 14.45
- DNTH 11.61
About VRE Veris Residential Inc.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.